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Abstract
Background: Heterozygous variants in CNTNAP2 have been implicated in a wide range of neurological phenotypes,
including intellectual disability (ID), epilepsy, autistic spectrum disorder (ASD), and impaired language. However,
heterozygous variants can also be found in unaffected individuals. Biallelic CNTNAP2 variants are rarer and cause a
well-defined genetic syndrome known as CASPR2 deficiency disorder, a condition characterised by ID, early-onset
refractory epilepsy, language impairment, and autistic features.
Case-report: A 7-year-old boy presented with hyperkinetic stereotyped movements that started during early
infancy and persisted over childhood. Abnormal movements consisted of rhythmic and repetitive shaking of the
four limbs, with evident stereotypic features. Additional clinical features included ID, attention deficit-hyperactivity
disorder (ADHD), ASD, and speech impairment, consistent with CASPR2 deficiency disorder. Whole-genome array
comparative genomic hybridization detected a maternally inherited 0.402 Mb duplication, which involved intron 1,
exon 2, and intron 2 of CNTNAP2 (c.97 +?_209-?dup). The affected region in intron 1 contains a binding site for the
transcription factor FOXP2, potentially leading to abnormal CNTNAP2 expression regulation. Sanger sequencing of
the coding region of CNTNAP2 also identified a paternally-inherited missense variant c.2752C > T, p.(Leu918Phe).
Conclusion: This case expands the molecular and phenotypic spectrum of CASPR2 deficiency disorder, suggesting
that Hyperkinetic stereotyped movements may be a rare, yet significant, clinical feature of this complex
neurological disorder. Furthermore, the identification of an in-frame, largely non-coding duplication in CNTNAP2
points to a sophisticated underlying molecular mechanism, likely involving impaired FOXP2 binding.
Keywords: CASPR2, Intragenic duplication, Hyperkinetic movement disorder, Hyperkinesia, Speech impairment,
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Background
Biallelic CNTNAP2 variants cause CASPR2 deficiency
disorder (CDD), a syndromic neurodevelopmental dis-
order involving refractory epilepsy, ID, language impair-
ment, and autistic features [1–4]. Heterozygous variants
in CNTNAP2 have also been identified in patients with a
wide range of complex neurological phenotypes, but
such variants can also be found in unaffected individuals
[5, 6].
CASPR2, the protein product of CNTNAP2, is a trans-
membrane cell adhesion molecule from the neurexin
family that is widely expressed throughout the brain [5,
7]. CASPR2 localises to juxtaparanodes of myelinated
axons, where it is involved in neuron-glia interactions,
and mediates the clustering of potassium channels via
interaction with contactin 2 (also known as TAG-1) [8,
9]. CASPR2 is also localised to the synapse where it is
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involved in several additional processes, such as neur-
onal migration, neurite development and synapse matur-
ation, stability, and function [10–14].
We describe a patient carrying compound heterozygous
variants in CNTNAP2 including a missense variant and an
intragenic duplication that were inherited from the father
and mother, respectively. In addition to the common fea-
tures found in CASPR2 deficiency disorder (ID, ADHD,
ASD, and speech impairment), the boy presented with pe-
culiar hyperkinetic stereotyped movements, expanding the
molecular and phenotypic spectrum of CDD.
Case presentation
This case was a 7-year-old boy without a family history
of neurodevelopmental disability, born at term to non-
consanguineous healthy parents (Fig. 1A) following a
twin pregnancy complicated by intrauterine growth re-
striction and preeclampsia. His dizygotic twin brother
was healthy at birth but was diagnosed with absence epi-
lepsy during infancy. The neonatal course was charac-
terised by feeding difficulties leading to failure to thrive.
At 3 months of age, recurrent episodes of crying associ-
ated with semi-continuous, repetitive jerky movements
of upper and lower limbs were observed, which were di-
agnosed as hyperkinetic stereotyped movements (Sup-
plementary Video 1).
These paroxysmal hyperkinetic-dyskinetic episodes re-
curred periodically without any trigger, lasted 10–12 h,
and mimicked infantile colics. Their frequency was tem-
porarily reduced when anti-reflux formulas and raniti-
dine were administered for concomitant recurrent
vomiting. Electroencephalogram and brain magnetic res-
onance imaging were unremarkable.
During his first years of life, the patient displayed
ADHD and autistic traits. The boy also featured a
phonological processing deficiency and clumsiness in
gross and fine movements was also observed. His neuro-
psychological evaluation (WPPSI-III at age 6 years) re-
vealed a global IQ of 71 (verbal, 86; performance, 68;
processing, 55). The movement disorder persisted during
the following years through non-triggered fast, high-
amplitude, rhythmic, continuous and repetitive shaking
involving the four limbs with stereotypic features (Sup-
plementary Videos 2–3). His stereotypic movement dis-
order had been misdiagnosed as tics before, which
indeed tend to appear from age 6–7 years [15]. However,
these repetitive movements already started before the
age of 3 and consisted of intense patterns of movement
that ran longer than tics and were more bilateral than
tics. Several medications, including carbamazepine, val-
proate, gabapentin, levodopa, flunarizine, benzodiaze-
pines, did not improve his symptoms. The boy is
currently receiving clonazepam, 0.2 mg/Kg in two daily
doses.
Genetic findings
Written informed consent was obtained from the pa-
tient’s parents. Whole-genome array-CGH on peripheral
blood genomic DNA of the family quartet revealed a
maternally inherited CNTNAP2 variant c.97 +?_209-
?dup in the proband. Real-time quantitative PCR con-
firmed that this 0.402 Mbp duplication involved part of
intron 1 and exon 2, with a breakpoint within intron 2
(Fig. 1C). This duplication is not predicted to introduce
a frameshift in the CASPR2 protein. The duplication
was not inherited by the sibling.
PCR amplification and Sanger sequencing was per-
formed to screen CNTNAP2 exons in the family, revealing
a paternally inherited missense variant c.2752C > T,
p.(Leu918Phe) in the proband (Fig. 1B). This variant is ab-
sent from the gnomAD dataset (https://gnomad.
broadinstitute.org/variant/) and affects a conserved resi-
due within the Laminin G-like (LG) 3 domain (GERP =
5.49). It is reported In ClinVar (allele ID 924741, https://
www.ncbi.nlm.nih.gov/clinvar/variation/949154/) and pre-
dicted damaging by in silico tools (e.g., DANN, 0.9977;
Mutation Taster, 1; CADD, 24.1). Both variants were ab-
sent in the proband’s sibling. Further details are available
in Supplementary Methods.
Discussion
The range of clinical symptoms found in patients har-
boring biallelic CNTNAP2 variants are collectively de-
scribed as CASPR2 deficiency disorder. Dyskinetic
features are not included amongst the classic neuro-
logical manifestations of this condition [1–4]. In this pa-
tient, we observed hyperkinetic stereotyped movements
consisting of continuous, repetitive and rhythmic shak-
ing of the four limbs, which became evident during the
first months of life and persisted over the years. These
abnormal movements did not resemble generalised dys-
tonia, paroxysmal non-kinesigenic dyskinesia, or parox-
ysmal kinesigenic dyskinesia, but rather represent a
novel neurological manifestation of CASPR2 deficiency
disorder. This dyskinetic phenotype may be related to
the role of CASPR2 in facilitating nerve conduction and
synaptic connectivity, particularly given its widespread
expression in the central and peripheral nervous system
[5, 9, 14]. In patients harboring biallelic variants in
CNTNAP2, brain MRI may be normal, such as in our
case, or show cortical dysplasia (cortical dysplasia-focal
epilepsy syndrome, CDFES).1–3 Additional findings in-
clude cerebellar abnormalities (vermian hypoplasia or at-
rophy) and nonspecific white matter abnormalities.1,2
The c.97 +?_209-?dup and p.(Leu918Phe) variants
were inherited from unaffected parents, supporting the
incomplete penetrance of heterozygous CNTNAP2 vari-
ants [5, 6]. The maternally inherited variant (c.97 +
?_209-?dup) involved a complete duplication of exon 2
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(99 bp) (Fig. 1D), which may negatively impact protein
folding and/or protein-protein interactions. Indeed, exon
2 encodes part of the discoidin homology domain, which
is found in the extracellular portion CASPR2 and is
known to mediate protein-protein interactions, pointing
to a potential perturbation of this mechanism in the pa-
tient (Fig. 1E). The paternally inherited missense variant
p.(Leu918Phe) is also in the extracellular portion of
CASPR2, but is found in the third LG domain (Fig. 1E).
Missense variants in the extracellular portion of CASPR2
have been shown to impair interactions with contactin 2
and affect axon growth in cortical neurons [12]. This
effect is likely related to the trans-synaptic bridge
formed in neurons by the interaction of CASPR2 and
contactin 2 that contributes to synaptic organization and
synaptic transmission [16]. It would therefore be of value
to determine if the variants identified in this patient have
functional consequences for protein-protein interactions,
or for synaptic or juxtaparanodal organisation and sig-
nalling. Such functional studies may shed light on why
heterozygous CNTNAP2 variants show incomplete pene-
trance and why biallelic mutations together produce a
range of phenotypes, including the novel motor pheno-
type described herein.
Fig. 1 Genetic findings in the reported patient. (A) Pedigree of the family showing the affected patient carrying compound heterozygous variants in CNTNAP2:
the paternally inherited missense c.2752C> T, p.(Leu918Phe) (ENST00000361727.3) in exon 17 and the maternally inherited c.97 +?_209-?dup duplication in
intron 1 (for which the exact breakpoints have not been mapped). (B) Sanger sequencing traces showing the heterozygous single nucleotide variant in the
proband and his father, consisting of leucine to phenylalanine substitution. (C) Confirmation of exon 2 duplication. RT-qPCR from genomic DNA shows that the
patient and his mother have one extra copy of exon 2 as compared to the father. The duplication breakpoint is located after exon 2 since the first ~ 200bp of
intron 2 are still duplicated. Three technical replicates per condition. (D) Localization of inherited mutations on CNTNAP2. The maternally inherited duplication
begins in the first intron and overlaps a binding site for the transcription factor FOXP2. Approximate boundaries of the duplication could be determined from
the array-CGH and PCRs (see also supp material), indicating that the duplication also involves exon 2 and part of intron 2. The paternally inherited mutation is
located in exon 17. (E) Predicted consequences of CNTNAP2 variants at the protein level. Exon 2 encodes the first part of the discoidin domain, the sequence of
which is duplicated by the maternally inherited c.97 +?_209-?dup variant. The paternally inherited p.(Leu918Phe) variant results in a amino acid change in exon
17, which encodes the third laminin G domain of CASPR2. Both domains belong to the extracellular region of CASPR2 which facilitates protein-protein
interactions. Supplementary data contain additional details on the methodology and results. Discoidin =Discoidin homology domain, Laminin G= Laminin G
domain, EGF= EGF-like domain, FBG= Fibrinogen-like region, TM= transmembrane domain, 4.1B = Protein 4.1 binding domain, PDZ=PDZ interaction domain
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The maternal duplication also has the potential to alter
the regulation of CNTNAP2. The transcription factor
FOXP2 targets a binding site in intron 1 of CNTNAP2
and regulates its expression. Mutations in FOXP2 are a
monogenic cause of childhood apraxia of speech
(SPCH1, OMIM #602081) [17] and CNTNAP2 is func-
tionally implicated in the aetiology of this condition as
part of the downstream network of FOXP2 target genes
[18]. This is supported by a genetic association of CNTN
AP2 variants with phonological memory performance in
children with specific language impairment [18]. Dupli-
cation of the FOXP2 target site in intron 1 of the mater-
nally inherited allele could alter FOXP2-mediated
regulation of CNTNAP2 and lead to aberrant CASPR2
levels, a hypothesis that needs functional testing in cell
or animal models. In this way, it is possible that the in-
tronic duplication could contribute to neurodevelop-
mental or speech phenotypes in patients that are related
to both FOXP2 and CNTNAP2, such as phonological
processing.
This study has two main limitations. First, a proper
functional characterization of the two detected CNTN
AP2 variants to evaluate their impact on protein struc-
ture and function could not performed. Second, it was
not possible to further investigate the presence of add-
itional variants with a potential modifier effect on the
clinical phenotype through Next Generation Sequencing
(NGS) techniques, such as whole exome sequencing
(WES) or whole genome sequencing (WGS).
Conclusion
This case of a boy with hyperkinetic stereotyped move-
ments and biallelic CNTNAP2 mutations expands our
knowledge about CNTNAP2-related disorders. It pre-
sents a new, rare neurological manifestation for CDD
and posits a remarkable molecular mechanism in which
coding and non-coding CNTNAP2 mutations could con-
tribute to the observed phenotypes. Accordingly, we sug-
gest screening CNTNAP2 regulatory regions in patients
with a CDD-suggestive phenotype even if a single het-
erozygous CNTNAP2 variant has been identified or if
atypical neurological phenotypes are also present. This
will lead to better diagnoses that can improve the man-
agement of patients with these disorders. This, together
with functional studies of the consequences of the iden-
tified mutations, will advance our scientific understand-
ing of disease genes like CNTNAP2.
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